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Abstract
Background: The DRAGON score, which includes clinical and computed 
tomographic (CT) scan parameters, predicts functional outcomes in ischemic 
stroke patients treated with intravenous tissue plasminogen activator (IV tPA). 
We assessed the utility of the DRAGON score in predicting functional outcome in 
stroke patients receiving both IV tPA and endovascular therapy.
Methods: A retrospective chart review of patients treated at our institution from 
February 2009 to October 2015 was conducted. All patients with computed 
tomography angiography (CTA) proven large vessel occlusions (LVO) who 
underwent intravenous thrombolysis and endovascular therapy were included. 
Baseline DRAGON scores and modified Rankin Score (mRS) at the time of hospital 
discharge was calculated. Good outcome was defined as mRS ≤3.
Results: Fifty‑eight patients with LVO of the anterior circulation were studied. The 
mean DRAGON score of patients on admission was 5.3 (range, 3–8). All patients 
received IV tPA and endovascular therapy. Multivariate analysis demonstrated 
that DRAGON scores ≥7 was associated with higher mRS (P < 0.006) and higher 
mortality (P < 0.0001) compared with DRAGON scores ≤6. Patients with DRAGON 
scores of 7 and 8 on admission had a mortality rate of 3.8% and 40%, respectively.
Conclusions: The DRAGON score can help predict better functional outcomes in 
ischemic stroke patients receiving both IV tPA and endovascular therapy. This data 
supports the use of the DRAGON score in selecting patients who could potentially 
benefit from more invasive therapies such as endovascular treatment. Larger 
prospective studies are warranted to further validate these results.
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INTRODUCTION
Intravenous tissue plasminogen activator (IV tPA) has 
been shown to improve functional outcomes in patients 
with acute ischemic strokes secondary to large vessel 
occlusions (LVO).[6] Despite this, IV tPA has a low rate of 
recanalization, and patients with LVO can further benefit 
from endovascular therapy.[3] To this end, the DRAGON 
score was designed to prognosticate patient outcomes 
after IV tPA therapy, as well as to identify patients who 
could benefit from further endovascular treatment.[4,12]
The DRAGON score is a 10‑point scoring system 
based on computed tomography (CT) findings of 
hypoDensity or a dense MCA sign, prestroke modified 
Rankin Scale (mRS), Age, Glucose level on admission, 
Onset‑to‑treatment time, and initial National Institutes 
of Health Stroke Score (NIHSS).[12] The score has shown 
good performance in predicting poor patient outcomes 
despite administration of IV tPA.[13]
Recent randomized clinical trials using modern 
endovascular techniques have demonstrated the efficacy 
of endovascular stroke therapy for treating patients with 
acute ischemic strokes from LVO.[1,7,11] At present, there is 
no data to suggest that the DRAGON score can predict 
functional outcome in stroke patients receiving both IV 
tPA and endovascular therapy. We sought to assess the 
utility of the DRAGON score in predicting functional 
outcome in anterior circulation stroke patients receiving 
both IV tPA and endovascular therapy.
MATERIALS AND METHODS
Institutional Review Board approval was obtained prior 
to study initiation. A retrospective chart review was 
conducted among anterior circulation ischemic stroke 
patients treated with IV tPA and endovascular therapy, with 
either the ADAPT technique or stent‑triever. The major 
inclusion criteria were anterior circulation LVO seen on 
computed tomography angiography (CTA) and age ≥18. 
Anterior circulation LVO was defined as occlusions of the 
internal carotid artery (ICA) and M1 and/or M2 segment 
of the middle cerebral artery (MCA). Baseline DRAGON 
scores [Table 1], details of the treatment, and clinical 
outcome at time of hospital discharge were determined.
All endovascular interventions were performed on a flat 
detector‑based biplane angiographic system under general 
anesthesia. Endovascular treatment included mechanical 
thrombectomy with or without intraarterial thrombolysis 
(intraarterial tissue plasminogen activator). Mechanical 
thrombectomy was defined as a stentriever and/or direct 
aspiration via a large‑bore (≥5 Fr) intracranial reperfusion 
catheter. The degree of recanalization (Thrombolysis in 
Cerebral Infarction, TICI score) was determined at the 
end of the case by an endovascular surgeon.
The primary clinical outcome was the modified Rankin Scale 
(mRS) score at discharge. All mRS scores were reported 
on physical therapy progress notes and reviewed by stroke 
neurologists. Good outcome was defined as a mRS score 0–3 
and poor outcome as mRS 4–6 (death or dependency).
Univariate analysis for predictors of outcome were 
determined using the 2 and Student’s t‑test. Means 
were compared using the Student’s t‑test (two‑tailed), 
and percentages were compared using the 2 test. 
P values ≤0.05 were considered significant. Statistical 
analysis was performed using NCSS Statistical Software 
Inc V10.0 (Salt Lake City, Utah).
RESULTS
During the study period, a total of 58 patients met the 
inclusion criteria [Table 2]. The mean patient age was 
61.4 years, and the mean National Institutes of Health 
Stroke Scale (NIHSS) score was 15.6 (range 6–36). In our 
study population, there were no patients with a DRAGON 
score of 0–2 and 9–10. There was no significant difference 
in age or NIHSS between patients with good clinical 
outcomes (mRS ≤3) and those with poor clinical outcomes 
(mRS ≥4). Pretreatment DRAGON scores and percentage 
of good outcomes at discharge are shown in Table 3.
Table 1: The DRAGON score
Variable Category Points
(Hyper) Dense cerebral artery 
sign or early infarct signs on 
admission CT head scan
None 0
Either of them 1
Both 2
mRS Score >1, prestroke No 0
Yes 1
Age <65 years 0
65-79 years 1
≥80 years 2




Onset-to-treatment time ≤90 min 0
>90 min 1




CT: Computed tomography, mRS: Modified Rankin Score, NIHSS: National Institutes 
of Health Stroke Scale
Key Words: Endovascular thrombectomy, ischemic stroke, large vessel occlusion, 
tissue plasminogen activator
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The highest and lowest percentage of good 
outcomes (mRS ≤ 3) was found in patients with a 
DRAGON score of 3 and 8, respectively. With increasing 
DRAGON scores, worse clinical outcome (mRS ≥ 4) 
was observed [Figure 1]. Mortality rates of 3.8% and 40% 
were observed in patients with DRAGON scores of 7 and 
8, respectively.
The association between subgroups of DRAGON scores 
and mRS and mortality rate is shown in Figure 2. 
DRAGON scores were grouped into high (score of 
7–8), intermediate (score of 5–6), and low (score of 
3–4) subgroups. High DRAGON scores were associated 
with higher mRS scores (average 4.8 ± 0.3; P < 0.006) 
compared with intermediate scores (average mRS 
2.6 ± 0.4) and low scores (average mRS 2.2 ± 0.5). High 
DRAGON scores (7–8) were also associated with higher 
mortality (40%; P < 0.0001) compared with intermediate 
and low DRAGON scores (3.8% and 0%, respectively).
DISCUSSION
The DRAGON score was originally proposed as an 
easy way of identifying patients who should be given 
additional therapeutic interventions (i.e., endovascular, 
hypothermia) due to poor functional outcomes after 
IV tPA.[12] The score takes into account various initial 
prognosticating factors (age, initial NIHSS, time from 
onset, CT image findings, and blood sugar levels) 
and provides relevance based on multivariate logistic 
regression. Strbian et al. showed the predicative value of 
their scoring system by demonstrating that patients with 
DRAGON scores of 8 and 9–10 carried a 70% and 100% 
proportion of miserable outcomes (mRS ≥5, bedridden, 
incontinent, requiring constant nursing care, or dead), 
respectively, compared to patients with lower DRAGON 
scores.[4] These patients could be suitable for additional 
rescue therapies such as endovascular intervention.
Although the DRAGON score has been validated by 
several centers across the world, there are no studies 
investigating the utility of the score in predicting 
functional outcomes of patients receiving both IV tPA 
and endovascular therapy.[2,4,9,13] The results of our study 
show that patients with a DRAGON score of 7–8 had 
significantly worse clinical outcomes (mRS ≥4) and 
higher mortality compared to patients with DRAGON 
scores ≤6. This demonstrates that the DRAGON score 
can predict patient clinical outcomes after treatment 
with IV tPA and endovascular therapy. In addition, the 
score can be used to select patients who could benefit 
from endovascular intervention.
There exist a few scoring systems in the literature that 
have shown promise in predicting the clinical outcome, 
Table 2: Baseline characteristics of patients







Age, mean (range) 61.4 (32-85) 57.8 66.2 0.018
NIHSS, mean (range) 15.6 (6-36) 14.1 17.5 0.019
DRAGON Score
0-2 0 - -
3 10 (17%) 8 2
4 7 (12%) 4 3
5 19 (33%) 15 4
6 7 (12%) 4 3
7 10 (17%) 2 8
8 5 (9%) 0 5
9-10 0 - -
mRS: Modified Rankin Score at discharge, NIHSS: National Institutes of Health Stroke 
Scale
Table 3: DRAGON Scores, average mRS at discharge, 
and % good outcome of the 58 patients







mRS: Modified Rankin Score, % Good outcome (defined as mRS ≤3 at time of discharge)
Figure 1: Clinical outcome at discharge according to the DRAGON 
score
Figure 2: Correlation between DRAGON score and mRS and 
mortality
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and thus, appropriately select patients for endovascular 
therapy. The CTA collateral score, based on the degree 
of collateral circulation on pretreatment CTA, has been 
shown to predict smaller infarct volumes and better 
clinical outcomes in patients after recanalization with 
endovascular intervention.[5] The Capillary Index Score, 
based on a preintervention cerebral angiogram, can 
predict favorable outcomes in patients with ischemic 
strokes.[8] Similarly, the PRE (Pittsburgh Response to 
Endovascular therapy) score, which incorporates age, 
admission NIHSS, and ASPECT score on head CT, can 
predict outcomes and facilitates selection for patients 
who could benefit from endovascular intervention.[10]
Compared with other scoring systems, the DRAGON 
score is (1) fast to obtain, (2) consists of parameters 
known at admission, and (3) has a low cost; free.[2,4,9,13] 
Our study results show that the DRAGON score can in 
fact be applied to endovascular patients who have already 
received IV tPA.
A few limitations need to be acknowledged in our 
current study. First, despite controlling for established 
stroke outcome predictors, we cannot rule out 
additional baseline confounding variables that can 
affect patient outcomes. Second, this study uses data 
from only one center. Our aim was to apply an already 
established scoring system towards predicting stroke 
outcomes rather than investigate a novel prognostic 
tool. Third, as we only included anterior circulation 
strokes, our study results cannot be applied to posterior 
circulation strokes. Further data is needed to determine 
if the DRAGON score can be adapted for posterior 
circulation strokes.
CONCLUSIONS
The DRAGON score is a fast and easy score to obtain that 
can predict the functional outcomes of acute ischemic 
stroke patients treated with IV tPA and endovascular 
therapy. Larger prospective studies and external validation 
of the score as it applies to both IV tPA and endovascular 
therapy is warranted.
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